*Values are the number of studies that found that particular result for the respective predictors. †The first number in this column refers to the number of studies that performed a multivariate analysis disconfirming the univariate finding (studies in which the multivariate analysis confirmed the univariate finding, are shown in the columns labelled − and +, respectively). The second number in this column refers to the number of studies that did not perform a multivariate analysis. ‡In studies that evaluated onset categories oligoarticular, polyarticular and systemic, results have been duplicated for oligoarthritis persistent and extended, and polyarthritis RF-positive and RF-negative, respectively. −, lower chance of favourable outcome in multivariate analysis (p≤0.05); <, lower chance of favourable outcome in univariate analysis (p≤0.05); NS, not significant (p>0.05); S, significant in univariate analysis. Direction of the effect not shown (p≤0.05); >, higher chance of favourable outcome in univariate analysis (p≤0.05); +, higher chance of favourable outcome in multivariate analysis (p≤0.05).

ANA, antinuclear antibodies; CRP, C-reactive protein; ERA, enthesitis-related arthritis; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigens; IL, interleukin; JIA, Juvenile idiopathic arthritis; PGA, physician's global assessment; RF, rheumatoid factor; TGF, transforming growth factor.